Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. METHODS: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P<0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%). CONCLUSIONS: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [14]
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Research works printed but not linked: 2
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
Cited by
Items 601–700 of 1,025
Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats.
Lu, Y., Zhou, N., Huang, X., Cheng, J.-W., Li, F., Wei, R.-L., & Cai, J.-P. (2014) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2014.01.01 · Cited by 69
Antiangiogenic Therapy for Cancer: An Update
Shojaei, F., & Ferrara, N. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e31815a7b69 · Cited by 72
miRNAs as potential therapeutic targets for age-related macular degeneration
Wang, S., Koster, K. M., He, Y., & Zhou, Q. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.176 · Cited by 67
INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION COMPLICATING PATHOLOGIC MYOPIA
Lalloum, F., Souied, E. H., Bastuji‐Garin, S., Puche, N., Querques, G., Glacet-Bernard, A., COSCAS, G. J., Soubrane, G., & Leveziel, N. (2010) · Retina · doi:10.1097/iae.0b013e3181bcef24 · Cited by 67
Self-citationEmerging Pharmacologic Therapies for Wet Age-Related Macular Degeneration
Ni, Z., & Hui, P. (2009) · Ophthalmologica · doi:10.1159/000228926 · Cited by 67
“716 patients with minimal classic or occult CNV secondary to AMD were treated with a 0.3- or 0.5-mg dose of Lucentis IVT or sham injections monthly. The results demonstrated that 94.5 and 94.6p of Lucentis-treated patients lost fewer than 15 letters (0.3 and 0.5 mg, respectively), compared with 62p of sham-treated pat…”
ResultInfluentialOuter Retinal Corrugations in Age-Related Macular Degeneration
Ooto, S., Vongkulsiri, S., Sato, T., Suzuki, M., Curcio, C. A., & Spaide, R. F. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1871 · Cited by 65
Recombinant Human VEGF 165 b Inhibits Experimental Choroidal Neovascularization
Hua, J., Spee, C. K., Kase, S., Rennel, E., Magnussen, A., Qiu, Y., Varey, A. H. R., Dhayade, S., Churchill, A., Harper, S. J., et al. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4360 · Cited by 75
“01 to 1 g/mL, or an effective dose in humans of 3 g/eye, 1000- to 10-fold lower than ranibizumab or bevacizumab.(35) Ranibizumab and bevacizumab are both human specific, so it is not possible to compare directly the relative efficacies in mice.”
BackgroundGiani, A., Luiselli, C., Esmaili, D. D., Salvetti, P., Cigada, M., Miller, J. W., & Staurenghi, G. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6617 · Cited by 67
“More recently, optical coherence tomography (OCT)7 has become a fundamental tool in the diagnosis and follow-up of this disease.8 The pivotal minimally classic/occult trial of the anti–vascular endothelial growth factor (VEGF) antibody ranibizumab in the treatment of neovascular AMD and the anti-VEGF antibody for the…”
BackgroundChew, E. Y., Clemons, T. E., Bressler, S. B., Elman, M. J., Danis, R. P., Domalpally, A., Heier, J. S., Kim, J. E., & Garfinkel, R. A. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.02.003 · Cited by 67
“Current therapy for neovascular AMD, intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents, such as bevacizumab, ranibizumab and aflibercept, can potentially stabilize visual acuity in 95% of eyes [5–10].”
Self-citationSayanagi, K., Sharma, S., & Kaiser, P. K. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.151977 · Cited by 67
Self-citationBrar, V. S., Sharma, R. K., Murthy, R. K., & Chalam, K. V. (2010) · PubMed Central · Cited by 68
Schnichels, S., Hagemann, U., Januschowski, K., Hofmann, J., Bartz‐Schmidt, K. U., Szurman, P., Spitzer, M. S., & Aisenbrey, S. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303130 · Cited by 69
Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema
Russo, A., Costagliola, C., Delcassi, L., Parmeggiani, F., Romano, M. R., dell’Omo, R., & Semeraro, F. (2013) · Mediators of Inflammation · doi:10.1155/2013/476525 · Cited by 73
“While significant differences in the reduction of intraocular inflammation after cataract surgery were not observed [55, 56, 59], NSAIDs were more effective at reestablishing the blood-aqueous barrier as indicated by flare, which was measured via either slit-lamp examination or fluorophotometry…”
MethodGale, R. P., Mahmood, S., Devonport, H., Patel, P. J., Ross, A. H., Walters, G., Downey, L., Elsherbiny, S., Freeman, M., Berry, S., et al. (2019) · Eye · doi:10.1038/s41433-018-0300-3 · Cited by 72
Holz, F. G., Korobelnik, J.-F., Lanzetta, P., Mitchell, P., Schmidt-Erfurth, U., Wolf, S., Markabi, S., Schmidli, H., & Weichselberger, A. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3813 · Cited by 66
Toalster, N., Russell, M. W., & Ng, P. (2013) · Retina · doi:10.1097/iae.0b013e3182831265 · Cited by 66
“2 letter improvement, respectively.(1,2) The IaE arm in Oubraham et al(15) also showed an improvement of 10.”
BackgroundResultInfluentialShort-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic
Borrelli, E., Grosso, D., Vella, G., Sacconi, R., Battista, M., Querques, L., Zucchiatti, I., Prascina, F., Bandello, F. M., & Querques, G. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04955-7 · Cited by 69
Chaikitmongkol, V., Sagong, M., Lai, T. Y. Y., Tan, G. S. W., Ngah, N. F., Ohji, M., Mitchell, P., Yang, C.-H., Ruamviboonsuk, P., Wong, I., et al. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000445 · Cited by 75
Hanson, R. L. W., Airody, A., Sivaprasad, S., & Gale, R. P. (2022) · Eye · doi:10.1038/s41433-022-02360-4 · Cited by 75
Rush, R. B. (2023) · Clinical ophthalmology · doi:10.2147/opth.s424315 · Cited by 67
“Introduction The introduction of intravitreal anti–VEGF treatments has resulted in considerable improvements in outcomes for patients with neovascular age-related macular degeneration (nAMD).(1,2) However, a variety of limitations to antiVEGF treatment in the management of nAMD exist, including the constraint of repet…”
BackgroundRobbie, S. J., von Leithner, P. L., Ju, M., Lange, C., King, A. G., Adamson, P., Lee, D. M., Sychterz, C. J., Coffey, P. J., Ng, Y., et al. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10169 · Cited by 67
Retinal and choroidal microangiopathies: Therapeutic opportunities
Afzal, A., Shaw, L. C., Ljubimov, A. V., Boulton, M. E., Segal, M. S., & Grant, M. B. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.04.011 · Cited by 78
Lad, E. M., Hammill, B. G., Qualls, L. G., Wang, F., Cousins, S. W., & Curtis, L. H. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.05.014 · Cited by 68
“The landmark phase 3 studies—the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trial and the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA)—showed that continuous monthly intravitreous inject…”
BackgroundIntravitreal Injection of Normal Saline Induces Retinal Degeneration in the C57BL/6J Mouse
Hombrebueno, J. R., Luo, C., Guo, L., Chen, M., & Xu, H. (2014) · Translational Vision Science & Technology · doi:10.1167/tvst.3.2.3 · Cited by 67
Treatment of diabetic retinopathy with anti‐VEGF drugs
Waisbourd, M., Goldstein, M., & Loewenstein, A. (2010) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2010.02010.x · Cited by 66
Stahl, A., Paschek, L., Martin, G., Gross, N. J., Feltgen, N., Hansen, L. L., & Agostini, H. T. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.08.005 · Cited by 66
CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION: Today’s and Future Treatments
Vélez-Montoya, R., Oliver, S. C. N., Olson, J. L., Fine, S. L., Mandava, N., & Quiroz-Mercado, H. (2012) · Retina · doi:10.1097/iae.0b013e318271f265 · Cited by 76
“Most of the studies agreed in their results by reporting an increase in the number of cases but without reaching statistical difference with the control arms.(45,46,50) However, it is important to note that because most of the studies were not powered to detect small differences in adverse event rates, no definite con…”
ResultSteel (2010) · Clinical Ophthalmology · doi:10.2147/opth.s10060 · Cited by 65
Toth, C. A., Decroos, F. C., Ying, G.-S., Stinnett, S. S., Heydary, C. S., Burns, R., Maguire, M., Martin, D., & Jaffe, G. J. (2015) · Retina · doi:10.1097/iae.0000000000000483 · Cited by 66
Kitchens, J. W., Diana, V., Boyer, D. S., Thompson, D. E., Gibson, A., Saroj, N., Vitti, R., Berliner, A. J., & Kaiser, P. K. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.046 · Cited by 68
Self-citationPreferred therapies for neovascular age-related macular degeneration
Chiang, A., & Regillo, C. D. (2011) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32834597d9 · Cited by 68
Liu, J., Zhang, X., Li, G., Xu, F., Li, S., Teng, L., Li, Y., & Sun, F. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s217038 · Cited by 64
Mukwaya, A., Jensen, L. D., & Lagali, N. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00566-2 · Cited by 72
Novel and investigational therapies for wet and dry age-related macular degeneration
Sarkar, A., Sodha, S., Junnuthula, V., Kolimi, P., & Dyawanapelly, S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.04.013 · Cited by 68
Age-Related Macular Degeneration: Clinical Findings, Histopathology and Imaging Techniques
Zarbin, M. A., Casaroli-Marano, R. P., & Rosenfeld, P. J. (2014) · Developments in ophthalmology · doi:10.1159/000358536 · Cited by 82
Goff, M. J., Johnson, R. N., McDonald, H. R., Ai, E., Jumper, J. M., & Fu, A. D. (2007) · Retina · doi:10.1097/iae.0b013e318042b53f · Cited by 65
Systemic Vascular Safety of Ranibizumab for Age-Related Macular Degeneration
Ueta, T., Noda, Y., Toyama, T., Yamaguchi, T., & Amano, S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.022 · Cited by 70
From Pathobiology to the Targeting of Pericytes for the Treatment of Diabetic Retinopathy
Arboleda‐Velásquez, J. F., Valdez, C. N., Marko, C. K., & D'Amore, P. A. (2015) · Current Diabetes Reports · doi:10.1007/s11892-014-0573-2 · Cited by 69
Minassian, D. C., Reidy, A., Lightstone, A., & Desai, P. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.195370 · Cited by 65
A Very Effective Treatment for Neovascular Macular Degeneration
Stone, E. M. (2006) · New England Journal of Medicine · doi:10.1056/nejme068191 · Cited by 74
Lotery, A. J., Gibson, J., Cree, A. J., Downes, S. M., Harding, S. P., Rogers, C. A., Reeves, B. C., Ennis, S., & Chakravarthy, U. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.07.046 · Cited by 64
Sadda, S. R., Abdelfattah, N. S., Lei, J., Shi, Y., Marion, K. M., Morgenthien, E. A., Gune, S., & Balasubramanian, S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.031 · Cited by 70
Bashshur, Z. F., Haddad, Z. A., Schakal, A., Jaafar, R. F., Saad, A., & Noureddin, B. N. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.02.006 · Cited by 75
CD11c+ macrophages are proangiogenic and necessary for experimental choroidal neovascularization
Droho, S., Rajesh, A., Cuda, C. M., Perlman, H., & Lavine, J. A. (2023) · JCI Insight · doi:10.1172/jci.insight.168142 · Cited by 70
“Current therapy includes frequent intravitreal anti–vascular endothelial growth factor (VEGF) injections (3, 4).”
Intravitreal injections: a review of the evidence for best practice
Fagan, X. J., & Al‐Qureshi, S. (2012) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12026 · Cited by 67
Kawashima, Y., Oishi, A., Tsujikawa, A., Yamashiro, K., Miyake, M., Ueda‐Arakawa, N., Yoshikawa, M., Takahashi, A., & Yoshimura, N. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2838-5 · Cited by 69
“Although this treatment approach has dramatically improved visual outcomes [2, 3], achieving complete remission is still difficult [4], and a certain percentage of patients are refractory to the treatment or exhibit frequent recurrences after treatment [5–8].”
BackgroundCarneiro, Â. M., Barthelmes, D., Falcão, M. S., Mendonça, L. S., Fonseca, S. L., Gonçalves, R. M., Faria-Correia, F., & Falcão‐Reis, F. (2011) · Ophthalmologica · doi:10.1159/000323943 · Cited by 71
Christoforidis, J. B., Carlton, M. M., Knopp, M. V., & Hinkle, G. H. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6862 · Cited by 63
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
Ohr, M. P., & Kaiser, P. K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.658368 · Cited by 65
“In the ANCHOR (anti-VEGF antibody for the treatment of predominantly classic choroidal neovascularization in AMD) study, a randomized, controlled, double-masked, Phase III clinical trial, patients treated with ranibizumab were compared with patients treated with PDT and verteporfin [20,21].”
MethodSelf-citationCHANG, M. A., Diana, V., Bressler, S. B., Cassard, S. D., Gower, E. W., & Bressler, N. M. (2010) · Retina · doi:10.1097/iae.0b013e3181dd6d8a · Cited by 65
“Another Phase III trial comparing ranibizumab to photodynamic therapy for predominantly classic lesions (ANCHOR) showed similar results.(7) While our results are not as favorable, patients with predominantly hemorrhagic lesions specifically were excluded from these trials.”
ResultIntravitreal Ranibizumab and Bevacizumab: A Review of Risk
Dafer, R. M., Schneck, M., Friberg, T. R., & Jay, W. M. (2007) · Seminars in Ophthalmology · doi:10.1080/08820530701543024 · Cited by 64
Gene therapy for age-related macular degeneration
Moore, N. A., Bracha, P., Hussain, R. M., Morral, N., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356817 · Cited by 63
Costagliola, C., Agnifili, L., Arcidiacono, B., Duse, S., Fasanella, V., Mastropasqua, R., Verolino, M., & Semeraro, F. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707176 · Cited by 64
Joussen, A. M., Wolf, S., Kaiser, P. K., Boyer, D. S., Schmelter, T., Sandbrink, R., Zeitz, O., Deeg, G., Richter, A., Zimmermann, T., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13794 · Cited by 67
Self-citationA Hierarchical Mechanotransduction System: From Macro to Micro
Cao, R. Y., Tian, H., Tian, Y., & Fu, X. (2023) · Advanced Science · doi:10.1002/advs.202302327 · Cited by 74
Carneiro, Â. M., Falcão, M. S., Pirraco, A., Milheiro–Oliveira, P., Falcão‐Reis, F., & Soares, R. A. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.11.011 · Cited by 67
Calvo-González, C., Reche-Frutos, J., Donate-López, J., Fernández, C., & Garcia-Sanchez, J. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.09.021 · Cited by 65
Yoon, J. U., Byun, Y., & Koh, H. J. (2010) · Retina · doi:10.1097/iae.0b013e3181bd2fe4 · Cited by 63
Local therapies for inflammatory eye disease in translation: past, present and future
Tempest-Roe, S., Joshi, L., Dick, A. D., & Taylor, S. R. J. (2013) · BMC Ophthalmology · doi:10.1186/1471-2415-13-39 · Cited by 63
“The risk of serious cardiovascular events also remains controversial [77,78].”
Khurana, R. N., Dupas, B., & Bressler, N. M. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.11.039 · Cited by 63
Intravitreal injections: is there benefit for a theatre setting?
Abell, R. G., Kerr, N. M., Allen, P., & Vote, B. J. T. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-302030 · Cited by 63
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Maguire, M. G., & Martin, D. F. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.109 · Cited by 62
Monitoring Ocular Drug Therapy by Analysis of Aqueous Samples
Campochiaro, P. A., Choy, D. F., Diana, V., Hafiz, G., Shah, S. M., Nguyen, Q. D., Rubio, R. G., & Arron, J. R. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.04.038 · Cited by 63
Advances in Age-related Macular Degeneration Understanding and Therapy
Miller, J. W., Bagheri, S., & Vavvas, D. G. (2017) · touchREVIEWS in Ophthalmology · doi:10.17925/usor.2017.10.02.119 · Cited by 82
Framme, C., Eter, N., Hamacher, T., Hasanbasic, Z., Jochmann, C., Johnson, K. T. M., Kahl, M., Sachs, H. G., Schilling, H., Thelen, U., et al. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.09.017 · Cited by 68
Some activities of PorphyChem illustrated by the applications of porphyrinoids in PDT, PIT and PDI
Habermeyer, B., & Guilard, R. (2018) · Photochemical & Photobiological Sciences · doi:10.1039/c8pp00222c · Cited by 66
Wan, C.-R., Muya, L. W., Kansara, V. S., & Ciulla, T. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020288 · Cited by 69
Treatment of choroidal neovascularization using intravitreal bevacizumab
Pedersen, R., Soliman, W. M., Lund‐Andersen, H., & Larsen, M. (2007) · Acta Ophthalmologica Scandinavica · doi:10.1111/j.1600-0420.2007.00895.x · Cited by 63
“, South San Francisco, CA, USA), an antibody fragment with broad vascular endothelial growth factor (VEGF)-subtype affinity, has shown remarkable results in neovascular age-related macular degeneration (AMD) (Gaudreault et al. 2005; Brown et al. 2006; Rosenfeld et al. 2006).”
BackgroundMethodVan wijngaarden, P., & Qureshi, S. H. (2008) · Clinical and Experimental Optometry · doi:10.1111/j.1444-0938.2008.00305.x · Cited by 63
Wickremasinghe, S., Janakan, V., Sandhu, S. S., Islam, A. F. M., Abedi, F., & Guymer, R. H. (2015) · Retina · doi:10.1097/iae.0000000000000902 · Cited by 62
“The pivotal randomized clinical trials, with ranibizumab and aflibercept have all shown impressive gains in mean visual acuity over 12 months and 24 months using a variety of treatment protocols.(1,2) In all pivotal trials, however, approximately 10% of the cohorts continued to experience a loss in visual acuity, desp…”
MethodCiulla, T. A., Hussain, R. M., Taraborelli, D., Pollack, J. S., & Williams, D. F. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.03.021 · Cited by 67
Casparis, H., Wolfensberger, T. J., Becker, M. D., Eich, G., Nicole, G. R. A. F., Ambresin, A., Mantel, I., & Michels, S. (2013) · Retina · doi:10.1097/iae.0b013e31829f74b0 · Cited by 65
Rauch, R., Weingessel, B., Maca, S. M., & Vécsei‐Marlovits, P. V. (2011) · Retina · doi:10.1097/iae.0b013e3182018df6 · Cited by 62
Mezad-Koursh, D., Goldstein, M., Heilwail, G., Zayit-Soudry, S., Loewenstein, A., & Barak, A. (2010) · Retina · doi:10.1097/iae.0b013e3181cd47ed · Cited by 61
Knecht, P. B., Michels, S., Sturm, V., Bosch, M. M., & Menke, M. N. (2009) · Retina · doi:10.1097/iae.0b013e3181aade74 · Cited by 63
Long-Term Follow-Up of Myopic Choroidal Neovascularization Treated with Ranibizumab
Franqueira, N., Cachulo, M. L., Pires, I., Fonseca, P., Marques, I. P., Figueira, J., & da Silva, R. M. (2011) · Ophthalmologica · doi:10.1159/000333213 · Cited by 62
Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review
Kaszubski, P. A., Ami, T. B., Saade, C., & Smith, R. T. (2016) · Ophthalmic Research · doi:10.1159/000443209 · Cited by 67
Sarraf, D., London, N. J. S., Khurana, R. N., Dugel, P. U., Gune, S., Hill, L., & Tuomi, L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.07.007 · Cited by 62
Adamis, A. P., Brittain, C. J., Dandekar, A., & Hopkins, J. J. (2020) · Eye · doi:10.1038/s41433-020-0895-z · Cited by 71
Red Meat and Chicken Consumption and Its Association With Age-related Macular Degeneration
Chong, E. W. T., Simpson, J. A., Robman, L. D., Hodge, A. M., Aung, K. Z., English, D. R., Giles, G. G., & Guymer, R. H. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwn393 · Cited by 72
Cohen, S. Y., Oubraham, H., Uzzan, J., Dubois, L., & Tadayoni, R. (2012) · Retina · doi:10.1097/iae.0b013e318240a516 · Cited by 61
“2 letters.(3) In both trials, monthly injections of ranibizumab allowed severe loss of visual acuity to be avoided in most of the treated eyes.”
BackgroundResultBinley, K., Widdowson, P. S., Kelleher, M., de Belin, J., Loader, J., Ferrige, G., Carlucci, M., Esapa, M., Chipchase, D., Angell-Manning, D., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.008 · Cited by 61
“…studies investigating ranibizumab, an anti-VEGF antibody treatment delivered intravitreally for treating AMD, observed a moderate short-term inflammatory response in both the anterior and posterior portions of treated eyes (Rasmussen et al. , 2003; Brown et al. , 2006; Rosenfeld et al ., 2006).”
Sadda, S. R., Guymer, R. H., Monés, J., Tufail, A., & Jaffe, G. J. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.11.010 · Cited by 69
Pandit, S. A., Momenaei, B., Wakabayashi, T., Mansour, H. A., Vemula, S., Durrani, A. F., Pashaee, B., Kazan, A. S., Ho, A. C., Klufas, M. A., et al. (2023) · Ophthalmology Retina · doi:10.1016/j.oret.2023.10.018 · Cited by 65
Kashani, A. H., Keane, P. A., Dustin, L., Walsh, A. C., & Sadda, S. R. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2691 · Cited by 63
Vascular endothelial growth factor-A: A multifunctional molecular player in diabetic retinopathy
Zhang, X., Bao, S., Hambly, B. D., & Gillies, M. C. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.07.011 · Cited by 69
for the Post-Injection Endophthalmitis Study Team, Storey, P. P., Dollin, M. L., Rayess, N., Pitcher, J. D., Reddy, S., VANDER, J. F., Hsu, J., & Garg, S. J. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3035-x · Cited by 61
Landa, G., Amde, W., Doshi, V., Ali, A. M. M., McGevna, L., Gentile, R. C., Muldoon, T. O., Walsh, J. B., & Rosen, R. B. (2009) · Ophthalmologica · doi:10.1159/000227783 · Cited by 62
Glanville, J., Patterson, J. V., McCool, R., Ferreira, A., Gairy, K., & Pearce, I. (2014) · BMC Ophthalmology · doi:10.1186/1471-2415-14-7 · Cited by 61
“These findings are consistent with the safety profile observed for ranibizumab in other ocular conditions, including a low incidence of endophthalmitis, few ocular SAEs, and low rates of adverse systemic cardiovascular and cerebrovascular effects (for which there is an increased theoretical risk when using anti-VEGF a…”
BackgroundResultRepression of Choroidal Neovascularization Through Actin Cytoskeleton Pathways by MicroRNA-24
Zhou, Q., Anderson, C. A., Zhang, H., Li, X., Inglis, F. M., Jayagopal, A., & Wang, S. (2013) · Molecular Therapy · doi:10.1038/mt.2013.243 · Cited by 63
Stem Cells as Tools in Regenerative Therapy for Retinal Degeneration
Enzmann, V., Yolcu, E., Kaplan, H. J., & Ildstad, S. T. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.65 · Cited by 65
Arevalo, J. F., Lasave, A. F., Wu, L., Acón, D., Berrocal, M. H., Diaz-Llopis, M., Gallego-Pinazo, R., Serrano, M. A., Alezzandrini, A. A., Rojas, S., et al. (2016) · Retina · doi:10.1097/iae.0000000000000827 · Cited by 60
“Discussion Vascular endothelial growth factor inhibition is currently considered the treatment of choice of neovascular AMD.”
BackgroundInfluentialChaudhary, V., Matonti, F., Zarranz‐Ventura, J., & Stewart, M. W. (2021) · Retina · doi:10.1097/iae.0000000000003283 · Cited by 64
Ueno, S., Pease, M. E., Wersinger, D. M. B., Masuda, T., Vinores, S. A., Licht, T., Zack, D. J., Quigley, H., Keshet, E., & Campochiaro, P. A. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21445 · Cited by 61
“…did not cause improvement and merely slowed the rate of vision loss, intraocular injections of ranibizumab, an Fab fragment that binds all isoforms of VEGF-A, caused significant improvement in 30–40% of patients that was sustained for at least 2 years (Brown et al., 2006; Rosenfeld et al., 2006).”
BackgroundEndophthalmitis After Intravitreal Injections
Schwartz, S. G., Flynn, H. W., & Scott, I. U. (2009) · Springer eBooks · doi:10.1007/978-981-10-5260-6_14 · Cited by 60
Agawa, T., Usui, Y., Wakabayashi, Y., Okunuki, Y., Juan, M., Umazume, K., Kezuka, T., Takeuchi, M., Yamauchi, Y., & Gotô, H. (2014) · Retina · doi:10.1097/iae.0000000000000157 · Cited by 68
“Anti-VEGF antibody has been used in the treatment of AMD with satisfactorily outcomes.(3,4) Bevacizumab (Avastin; Roche, Basel, Switzerland) is a full-length, humanized monoclonal antibody that inhibits all isoforms of VEGF and was originally developed to treat metastatic carcinoma of the colon and rectum.”
MethodMantel, I., Deli, A., Iglesias, K., & Ambresin, A. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2090-9 · Cited by 63
“Recent therapeutic gains have been made following the demonstration that the inhibition of vascular endothelial growth factor A (VEGF-A) is an effective and safe therapy of neovascular age-related macular degeneration (nAMD) when using monthly injections of ranibizumab, a recombinant, humanized, monoclonal antibody fr…”
BackgroundLee, A., Lee, C. S., Butt, T., Xing, W., Johnston, R. L., Chakravarthy, U., Egan, C. A., Akerele, T., McKibbin, M., Downey, L., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-306229 · Cited by 65
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture
Miller, J. W. (2016) · Translational Vision Science & Technology · doi:10.1167/tvst.5.2.9 · Cited by 62
Subhi, Y., & Sørensen, T. L. (2017) · Journal of Ophthalmology · doi:10.1155/2017/7194927 · Cited by 66
“Thepivotal phase 3 trialsMARINAandANCHORstudies demonstrated that monthly Ranizbiumab (Lucentis, Novartis International AG, Basel, Switzerland) improved mean visual acuity for all subtypes of neovascular AMD [6, 7].”
Background
Metadata
- Authors
- Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S.
- Affiliations
- Houston Methodist (US)
- Cleveland Clinic (US)
- Retina Care Specialists (US)
- Ophthalmic Consultants of Boston (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1432-1444
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085712747
- Cited by
- 3,522
- References
- 19
- Citations by year
- 2026: 97 · 2025: 110 · 2024: 115 · 2023: 97 · 2022: 117 · 2021: 189 · 2020: 178 · 2019: 140 · 2018: 154 · 2017: 170 · 2016: 188 · 2015: 209 · 2014: 218 · 2013: 247 · 2012: 257
- FWCI
- 161.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, verteporfin, neovascular age-related macular degeneration, anti-VEGF therapy, photodynamic therapy, intravitreal injection, visual acuity, endophthalmitis, uveitis
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Visual Acuity, Photosensitizing Agents, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.